ClinicalTrials.gg
Not yet recruitingNCT07654660Updated Jun 17, 2026

Multimodal Conservative Intervention Versus Surgery for Chronic Refractory Plantar Fasciopathy

An interventional study of Multimodal Conservative Intervention and Endoscopic Plantar Fascial Release in Chronic Refractory Plantar Fasciopathy, sponsored by Universidad Europea de Valencia. Not yet recruiting at 1 site in Spain. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Universidad Europea de Valencia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Fasciitis, Plantar with a site in Spain — 5 open to participants now, 5 under way, none of them phase 3. Fasciitis, Plantar · Spain.

Planned enrollment
4th of 19
120 · median 48
Started
2026
with 1 other
No phase
17 of 20
4 open now
Registered
20th of 20
by date
Lead sponsor
1 of 20
Universidad Europea de Valencia

Among the 20 studies in Fasciitis, Plantar with a site in Spain, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, and was the 20th registered.

Fasciitis, Plantar

224 studies on the registry are indexed under Fasciitis, Plantar; 59 are open to participants now.

Browse Fasciitis, Plantar studies →

Open to participants now

5 of the 20 studies in Fasciitis, Plantar with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 29 Fasciitis, Plantar studies recruiting now, 5 (17%) set no upper age limit and 21 (72%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Fasciitis, Plantar with a site in Spain, or all of them as a file.
02

Study summary

Chronic refractory plantar fasciopathy is a common musculoskeletal condition that can cause persistent heel pain and functional limitations despite conservative treatment. When symptoms do not improve, patients often face the decision between continuing non-surgical management or undergoing surgery. However, direct comparative evidence between these treatment strategies is limited.

This multicenter controlled trial aims to compare the effectiveness of a multimodal conservative intervention consisting of manual therapy and ultrasound-guided percutaneous neuromodulation with endoscopic plantar fascial release followed by standard postoperative rehabilitation in adults with chronic refractory plantar fasciopathy.

A total of 120 participants will be allocated to treatment groups according to their informed treatment preference within a shared decision-making process. The primary outcome will be the change in the Foot Function Index (FFI) after 6 weeks. Secondary outcomes include pain intensity, health-related quality of life, treatment adherence, adverse events, and exploratory neurophysiological measures. The results are expected to provide evidence to support clinical decision-making and optimize the management of patients with chronic refractory plantar fasciopathy.

Read the detailed description

Chronic refractory plantar fasciopathy is one of the most common causes of persistent heel pain and is associated with substantial disability, reduced quality of life, and limitations in daily and occupational activities. Although most patients respond to conservative management, a subgroup continues to experience symptoms despite prolonged treatment and may be considered for surgical intervention. However, evidence directly comparing optimized multimodal conservative care with surgical management remains limited.

This multicenter, non-randomized controlled trial has been designed to evaluate the comparative effectiveness of these two therapeutic strategies under real-world clinical conditions. Participants will be allocated to treatment groups according to their informed treatment preference following a standardized shared decision-making process.

The experimental group will receive a 6-week multimodal conservative intervention consisting of manual therapy techniques and ultrasound-guided percutaneous neuromodulation delivered in 12 supervised sessions. The control group will undergo endoscopic plantar fascial release followed by a standardized postoperative rehabilitation program.

The primary outcome measure is the change in the Foot Function Index (FFI) at 6 weeks after treatment initiation. Secondary outcomes include pain intensity measured using the Visual Analog Scale (VAS), health-related quality of life assessed with the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L), treatment adherence, adverse events, and exploratory neurophysiological assessment through electromyography.

To minimize the effects of treatment selection bias inherent to the non-randomized design, analyses will include adjusted analysis of covariance (ANCOVA) and inverse probability of treatment weighting (IPTW). The findings of this study are expected to provide clinically relevant evidence to support shared decision-making and optimize treatment selection for patients with chronic refractory plantar fasciopathy.

03

Conditions studied

  • Chronic Refractory Plantar Fasciopathy

Browse trials for

Keywords

  • Plantar Fasciopathy
  • Plantar Fasciitis
  • Manual Therapy
  • Percutaneous Neuromodulation
  • Endoscopic Plantar Fasciotomy
  • Foot Function Index
  • Heel Pain
  • Conservative Treatment
  • Rehabilitation
  • Comparative Effectiveness
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 30 to 65 years.
  • Diagnosis of chronic plantar fasciopathy with symptom duration greater than 6 months.
  • Failure of at least two previous conservative treatments, each lasting at least 12 weeks.
  • Foot Function Index (FFI) total score ≥45 points.
  • Resting pain intensity ≥4/10 on the Visual Analog Scale (VAS).
  • Plantar fascia thickness ≥4 mm at the calcaneal insertion confirmed by ultrasound.
  • Ability to provide written and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Previous foot surgery on the affected side.
  • Calcaneal stress fracture.
  • (HbA1c) >7.5%.
  • Inability or unwillingness to comply with study procedures or follow-up assessments.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Multimodal Conservative Intervention

    Participants assigned to this arm will receive a 6-week multimodal conservative intervention consisting of manual therapy techniques combined with ultrasound-guided percutaneous neuromodulation, delivered in 12 supervised sessions (2 sessions per week).

    Procedure: Multimodal Conservative Intervention

  • Active comparator
    Surgical Management

    Participants assigned to this arm will undergo endoscopic plantar fascial release followed by a standardized postoperative rehabilitation program, including manual therapy during the rehabilitation period.

    Procedure: Endoscopic Plantar Fascial Release

Interventions

  • ProcedureMultimodal Conservative Intervention

    A 6-week multimodal conservative treatment including manual therapy techniques (gastrocnemius stretching, transverse friction massage, and tibial nerve neurodynamic mobilization) combined with ultrasound-guided percutaneous neuromodulation of the posterior tibial nerve using low-frequency electrical stimulation.

  • ProcedureEndoscopic Plantar Fascial Release

    Endoscopic plantar fascial release performed using a standardized surgical technique followed by a standardized postoperative rehabilitation program.

06

What researchers measure

Primary outcomes

  1. Change in Foot Function Index (FFI) total score

    The primary outcome is the change in the total Foot Function Index (FFI) score from baseline to 6 weeks after treatment initiation. The FFI is a validated patient-reported outcome measure assessing pain and functional disability related to foot disorders.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Change in pain intensity measured by the Visual Analog Scale (VAS)

    Pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS).

    Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks

  2. Change in health-related quality of life assessed by the EQ-5D-5L

    Health-related quality of life will be evaluated using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L).

    Time frame: Baseline, 6 weeks, and 12 weeks

  3. Treatment adherence

    Treatment adherence will be assessed as the proportion of scheduled sessions attended by participants.

    Time frame: During the 6-week intervention period

  4. Incidence of adverse events

    Adverse events will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From baseline through 12 weeks

Other outcomes

  1. Tibial nerve sensory conduction velocity assessed by electromyography

    Exploratory neurophysiological assessment of tibial nerve sensory conduction velocity measured by electromyography to investigate potential changes associated with the interventions.

    Time frame: Baseline and 12 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015 May 8;350:h2147. doi: 10.1136/bmj.h2147. No abstract available. PubMed 25956159 ↗
  • Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010 Sep 10;29(20):2137-48. doi: 10.1002/sim.3854. PubMed 20108233 ↗
  • Baxter DE, Thigpen CM. Heel pain--operative results. Foot Ankle. 1984 Jul-Aug;5(1):16-25. doi: 10.1177/107110078400500103. PubMed 6479759 ↗
  • Morrissey D, Cotchett M, Said J'Bari A, Prior T, Griffiths IB, Rathleff MS, Gulle H, Vicenzino B, Barton CJ. Management of plantar heel pain: a best practice guide informed by a systematic review, expert clinical reasoning and patient values. Br J Sports Med. 2021 Oct;55(19):1106-1118. doi: 10.1136/bjsports-2019-101970. Epub 2021 Mar 30. PubMed 33785535 ↗
  • Roy J. Applied Longitudinal Analysis , Second Edition, by G. M. Fitzmaurice, N. M. Laird, and J. H. Ware. J Biopharm Stat 2013; 23: 491-492.
  • Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014 Aug 1;35(29):1925-31. doi: 10.1093/eurheartj/ehu207. Epub 2014 Jun 4. PubMed 24898551 ↗
  • Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ. 2001 Nov 10;323(7321):1123-4. doi: 10.1136/bmj.323.7321.1123. No abstract available. PubMed 11701584 ↗
  • Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation fidelity. Implement Sci. 2007 Nov 30;2:40. doi: 10.1186/1748-5908-2-40. PubMed 18053122 ↗
  • Borrelli B. The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials. J Public Health Dent. 2011 Winter;71 Suppl 1:S52-63. PubMed 21656954 ↗
  • Al-Ashhab ME, Elbegawy HEA, Hasan HAA. Endoscopic Plantar Fasciotomy Through Two Medial Portals for the Treatment of Recalcitrant Plantar Fasciopathy. J Foot Ankle Surg. 2018 Mar-Apr;57(2):264-268. doi: 10.1053/j.jfas.2017.09.004. Epub 2017 Dec 7. PubMed 29224949 ↗
  • Cottom JM, Wolf JR, Sisovsky CA. Midterm Outcomes of Endoscopic Plantar Fascia Debridement in 125 Patients: A 5-Year Follow-Up. J Foot Ankle Surg. 2023 May-Jun;62(3):444-447. doi: 10.1053/j.jfas.2022.11.001. Epub 2022 Nov 10. PubMed 36443168 ↗
  • Chou AC, Ng SY, Koo KO. Endoscopic Plantar Fasciotomy Improves Early Postoperative Results: A Retrospective Comparison of Outcomes After Endoscopic Versus Open Plantar Fasciotomy. J Foot Ankle Surg. 2016 Jan-Feb;55(1):9-15. doi: 10.1053/j.jfas.2015.02.005. Epub 2015 May 23. PubMed 26007627 ↗
  • Eckenrode BJ, Kietrys DM, Parrott JS. Effectiveness of Manual Therapy for Pain and Self-reported Function in Individuals With Patellofemoral Pain: Systematic Review and Meta-analysis. J Orthop Sports Phys Ther. 2018 May;48(5):358-371. doi: 10.2519/jospt.2018.7243. Epub 2018 Jan 6. PubMed 29308698 ↗
  • De-la-Cruz-Torres B, Abuin-Porras V, Navarro-Flores E, Calvo-Lobo C, Romero-Morales C. Ultrasound-Guided Percutaneous Neuromodulation in Patients with Chronic Lateral Epicondylalgia: A Pilot Randomized Clinical Trial. Int J Environ Res Public Health. 2021 May 3;18(9):4877. doi: 10.3390/ijerph18094877. PubMed 34063673 ↗
  • Rayo-Perez AM, Juarez-Jimenez JM, Ortiz-Romero M, Gordillo-Fernandez LM, Garcia-De-La-Pena R. Comparative Effectiveness of Conservative Therapies for Plantar Fasciitis: A Retrospective Observational Study. Sports (Basel). 2025 Sep 5;13(9):306. doi: 10.3390/sports13090306. PubMed 41003612 ↗
  • Razzano C, Carbone S, Mangone M, Iannotta MR, Battaglia A, Santilli V. Treatment of Chronic Plantar Fasciitis with Noninvasive Interactive Neurostimulation: A Prospective Randomized Controlled Study. J Foot Ankle Surg. 2017 Jul-Aug;56(4):768-772. doi: 10.1053/j.jfas.2017.02.015. PubMed 28633774 ↗
  • Yelverton C, Rama S, Zipfel B. Manual therapy interventions in the treatment of plantar fasciitis: A comparison of three approaches. Health SA. 2019 Sep 25;24:1244. doi: 10.4102/hsag.v24i0.1244. eCollection 2019. PubMed 31934436 ↗
  • Zhong M, Yu B, Wang R, Qu B, Liu W, Shi S. Ultrasound-Guided Zhengqing Fengtongning vs Corticosteroid Injections for Plantar Fasciitis: A Randomized Controlled Trial on Short- and Long-Term Efficacy. Med Sci Monit. 2026 Feb 1;32:e950455. doi: 10.12659/MSM.950455. PubMed 41620820 ↗
  • Goff JD, Crawford R. Diagnosis and treatment of plantar fasciitis. Am Fam Physician. 2011 Sep 15;84(6):676-82. PubMed 21916393 ↗
  • Eshraghi Y, Chakravarthy K, Strand NH, Shirvalkar P, Schuster NM, Abdallah RT, Vallejo R, Sayed D, Kim D, Kim C, Meacham K, Deer T; Translational Research Committee American Society of Pain and Neuroscience (ASPN). The American Society of Pain and Neuroscience (ASPN) Practical Guidelines to Study Design and Scientific Manuscript Preparation in Neuromodulation. J Pain Res. 2021 Apr 16;14:1027-1041. doi: 10.2147/JPR.S295502. eCollection 2021. PubMed 33889019 ↗
  • Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017 Jul 4;167(1):40-47. doi: 10.7326/M17-0046. Epub 2017 Jun 20. PubMed 28630973 ↗
  • Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle A-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Rev Panam Salud Publica. 2015 Dec;38(6):506-14. PubMed 27440100 ↗
  • Rhim HC, Kwon J, Park J, Borg-Stein J, Tenforde AS. A Systematic Review of Systematic Reviews on the Epidemiology, Evaluation, and Treatment of Plantar Fasciitis. Life (Basel). 2021 Nov 24;11(12):1287. doi: 10.3390/life11121287. PubMed 34947818 ↗
  • England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF Jr, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009 Jan 13;72(2):185-92. doi: 10.1212/01.wnl.0000336370.51010.a1. Epub 2008 Dec 3. PubMed 19056666 ↗
  • U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD, 2017.
  • Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001 Jul;33(5):337-43. doi: 10.3109/07853890109002087. PubMed 11491192 ↗
  • Budiman-Mak E, Conrad KJ, Roach KE. The Foot Function Index: a measure of foot pain and disability. J Clin Epidemiol. 1991;44(6):561-70. doi: 10.1016/0895-4356(91)90220-4. PubMed 2037861 ↗
  • Schwartz EN, Su J. Plantar fasciitis: a concise review. Perm J. 2014 Winter;18(1):e105-7. doi: 10.7812/TPP/13-113. PubMed 24626080 ↗
  • Renan-Ordine R, Alburquerque-Sendin F, de Souza DP, Cleland JA, Fernandez-de-Las-Penas C. Effectiveness of myofascial trigger point manual therapy combined with a self-stretching protocol for the management of plantar heel pain: a randomized controlled trial. J Orthop Sports Phys Ther. 2011 Feb;41(2):43-50. doi: 10.2519/jospt.2011.3504. Epub 2011 Jan 31. PubMed 21285525 ↗
  • Chou TA, Tzeng YH, Teng MH, Huang YC, Wang CS, Lin CC, Chiang CC. Trimalleolar Fractures Treated by Open Reduction Internal Fixation Compared With Arthroscopically Assisted Reduction and Minimally Invasive Surgery. Foot Ankle Int. 2023 May;44(5):431-442. doi: 10.1177/10711007231157676. Epub 2023 Mar 22. PubMed 36946569 ↗
  • Nery C, Coughlin MJ, Baumfeld D, Mann TS. Lesser metatarsophalangeal joint instability: prospective evaluation and repair of plantar plate and capsular insufficiency. Foot Ankle Int. 2012 Apr;33(4):301-11. doi: 10.3113/FAI.2012.0301. PubMed 22735202 ↗
  • DiGiovanni BF, Nawoczenski DA, Lintal ME, Moore EA, Murray JC, Wilding GE, Baumhauer JF. Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study. J Bone Joint Surg Am. 2003 Jul;85(7):1270-7. doi: 10.2106/00004623-200307000-00013. PubMed 12851352 ↗
  • Rathleff MS, Molgaard CM, Fredberg U, Kaalund S, Andersen KB, Jensen TT, Aaskov S, Olesen JL. High-load strength training improves outcome in patients with plantar fasciitis: A randomized controlled trial with 12-month follow-up. Scand J Med Sci Sports. 2015 Jun;25(3):e292-300. doi: 10.1111/sms.12313. Epub 2014 Aug 21. PubMed 25145882 ↗
  • Riddle DL, Schappert SM. Volume of ambulatory care visits and patterns of care for patients diagnosed with plantar fasciitis: a national study of medical doctors. Foot Ankle Int. 2004 May;25(5):303-10. doi: 10.1177/107110070402500505. PubMed 15134610 ↗
  • Monteagudo M, de Albornoz PM, Gutierrez B, Tabuenca J, Alvarez I. Plantar fasciopathy: A current concepts review. EFORT Open Rev. 2018 Aug 29;3(8):485-493. doi: 10.1302/2058-5241.3.170080. eCollection 2018 Aug. PubMed 30237906 ↗

Individual participant data

Plan to share: Undecided — At the time of study registration, no final decision has been made regarding the sharing of individual participant data (IPD). Any future data sharing will be considered in accordance with institutional policies, ethical approvals, participant consent, and applicable data protection regulations. If data sharing is approved, only de-identified data will be made available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2027, 9 months later.

Of 104 non-industry interventional studies with no phase under Fasciitis, Plantar, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's planned 9 months is below that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Sep 2027
CompletionEst.
Jan 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07654660
Lead sponsor
Universidad Europea de Valencia
Responsible party
Dr. Javier Bonastre Férez (Associate Professor of Physiotherapy, Universidad Europea de Valencia) — Principal investigator
First posted
Jun 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

Javier Bonastre Férez, PhD
Contact
javier.bonastre@universidadeuropea.es
+34644120315

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion